EcoDrugPlus

Dopamine Receptor D1b

Ensembl ID : ENSGACG00000020716
Gene Symbol: DRD1B
1 Cross references
200 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSGACG00000009131
Gene Symbol: DRD2A
1 Cross references
207 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSGACG00000003265
Gene Symbol: DRD3
1 Cross references
201 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSGACG00000008935
Gene Symbol: DRD4A
1 Cross references
174 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSGACG00000009688
Gene Symbol: ENPP2
1 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSGACG00000004174
Gene Symbol: EGLN1
1 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSGACG00000009469
Gene Symbol: EGLN2
1 Cross references
195 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSGACG00000011414
Gene Symbol: EPAS1B
1 Cross references
211 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSGACG00000004590
Gene Symbol: ECE1
1 Cross references
231 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSGACG00000017219
Gene Symbol: EDNRAA
2 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSGACG00000012901
Gene Symbol: EDNRB
2 Cross references
178 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSGACG00000004048
Gene Symbol: EDNRB
2 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).